Navigation Links
Stemline Therapeutics Announces Two Presentations of Direct Injection Synthetic Peptide Vaccine for Brain Cancer, Now Being Developed as SL-701, at the Annual Meeting of the American Association of Cancer Research (AACR)
Date:4/18/2012

NEW YORK, April 18, 2012 /PRNewswire/ -- Stemline Therapeutics, Inc. announced that trial results of two clinical studies of direct injection synthetic peptide vaccine, now being developed as SL-701, in both adults and children with advanced brain cancer were selected for late-breaking presentations at the Annual Meeting of the American Association for Cancer Research (AACR) held from March 31 to April 4, 2012 in Chicago, IL. SL-701 is comprised of synthetic peptides corresponding to epitopes of targets overexpressed on glioblastoma multiforme (GBM) and other high-grade and low-grade gliomas and administered via direct subcutaneous injection. The data were presented by investigators at the University of Pittsburgh (Pitt), who developed the direct injection synthetic peptide vaccine. In 2009, the University of Pittsburgh licensed patent rights relating to the vaccine to Stemline.

In the pediatric study conducted by the Pitt team and led by Dr. Ian Pollack, 27 children were enrolled, including 16 with newly diagnosed brainstem glioma (BSG), five with newly diagnosed cerebral high grade glioma (HGG), and six with recurrent gliomas. Children were treated with the Pitt synthetic peptide vaccine, administered via direct subcutaneous injection, every three weeks for up to eight courses. Among 22 evaluable children who were HLA-A2-positive, three had sustained partial responses (PRs) including one exceeding 15 months, one had prolonged disease free status following surgery, and 14 had stable disease lasting longer than three months. In addition, the results of ELISPOT immunological assays revealed specific T-cell responses to the intended targets in six of seven children evaluated. Systemic side effects were minimal. Tumor pseudoprogression, which is transient tumor enlargement due to inflammation followed by tumor stabilization or shrinkage, occurred in four children. The research team concluded that the direct injection synthetic peptide vaccine, now being developed by Stemline as SL-701, demonstrated both immunological and clinical activity in children with malignant glioma.

In the adult study, conducted at the University of Pittsburgh and other centers, adult patients with low-grade glioma (LGG) were treated with the Pitt vaccine via direct subcutaneous injection every three weeks for eight courses. Twenty-four HLA-A2-positive patients were enrolled, including 13 with newly diagnosed high-risk LGG without prior radiotherapy, one with newly diagnosed high-risk LGG with prior radiotherapy, and 10 with recurrent LGG. Side effects were minimal with one grade 3 fever. Sustained and specific immune responses, as assessed by ELISPOT assays, were observed in the majority of evaluable patients. The research team on the adult study led by Dr. Hideho Okada at Pitt, reported that, although a thorough evaluation of progression-free survival would require a longer observation period, among 17 patients who completed eight courses, 10 had stable disease. The team concluded that the Pitt vaccine, now being developed by Stemline as SL-701, was well tolerated and demonstrated immune responses in high risk adult patients with LGG.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Among Stemline's drug candidates are SL-401 and SL-701, both of which have demonstrated single agent clinical activity in Phase I/II studies of advanced cancer patients. In a multicenter Phase I/II trial in patients with advanced acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), SL-401 demonstrated single agent activity, including durable complete responses (CRs), and an overall survival (OS) improvement relative to historical data in the most heavily pretreated AML patients. In addition, SL-401 was well-tolerated and was not toxic to the bone marrow. SL-401 is being advanced into later stage trials in advanced AML. Stemline's second clinical stage therapeutic, SL-701, has demonstrated single agent activity including durable CRs and partial responses (PRs), as well as an OS benefit compared with historical data in Phase I/II trials of adult patients with refractory or recurrent glioblastoma and pediatric patients with malignant glioma. SL-701 is now poised for later stage trials in pediatric and adult patients with advanced brain cancer. Stemline is also developing a broad portfolio of preclinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from the Company's proprietary discovery platform, StemScreen®. For more information, please visit the Company's website at www.stemline.com.

Stemline Contact:

Mark Jacobson
Director, Corporate Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Sixth Floor
Tel: 646-502-2307
Email: mjacobson@stemline.com
www.stemline.com

 

 


'/>"/>
SOURCE Stemline Therapeutics, Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Stemline Therapeutics Appoints Kevin Buchi, Former CEO of Cephalon, to Its Board of Directors
2. Stemline Therapeutics, Inc. Names Eric K. Rowinsky, M.D. Chief Medical Officer and Head of Research and Development
3. Stemline Therapeutics Expands Clinical Oncology Program Directed at Cancer Stem Cells With Addition of M.D. Anderson Cancer Center
4. Nile Therapeutics, Inc. Completes $1.34 Million Registered Direct Offering
5. Nile Therapeutics, Inc. to Raise $1.4 Million in Registered Direct Offering
6. Amsterdam Molecular Therapeutics Announces Results of Extraordinary General Meeting
7. Particle Sciences and Pernix Therapeutics Enter into an Agreement to Develop a Pediatric Dermatology Product
8. Tarsa Therapeutics Signs Commercial Supply Agreement for its Ostora™ Oral Calcitonin Product With QS Pharma
9. Novation Releases Its Latest Transcatheter Cardiovascular Therapeutics Report to Help Members Understand and Prepare for New Technologies
10. Halo Therapeutics Reports Favorable Independent Review of Lead Drug Candidate HT-100
11. Echo Therapeutics, Inc. Announces 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... -- Research and Markets has announced the addition ... report to their offering. ... The World Market for Companion Diagnostics covers the world ... in the report includes the following: , ... by Region (N. America, EU, ROW), 2015-2020 , World ...
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. ... articles published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
(Date:6/24/2016)... Gaithersburg, MD (PRWEB) , ... June 24, 2016 ... ... and protocols for human induced pluripotent stem (iPS) cells and other difficult to ... PluriQ™ G9™ Cloning Medium. The PluriQ™ G9™ Gene Editing System is ...
Breaking Medicine News(10 mins):